Attached files
Table of Contents
SECURITIES AND EXCHANGE COMMISSION
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Nevada | 333-57514 | 95-4834274 | ||
(State or other jurisdiction | (Commission | (IRS Employer | ||
of incorporation) | File Number) | Identification Number) |
116 West Stocker Street, Glendale, California | 91202 | |
(Address of principal executive offices) | (Zip Code) |
[ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
[ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
[ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
[ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Table of Contents
Item 8.01. Other Events.
On February 2, 2010 the Company signed a letter of intent with RRML LLC to secure a collateralized 7.5 Million loan to finance its cash flow requirements for its scheduled pre-clinical studies and Phase I clinical trial. The company is currently in process updating all necessary regulatory fillings through a super 8K which will be filed shortly.
Item 9.01 Financial Statements and Exhibits
Exhibit No. Description
10.1 Agreement for Member of the Scientific Advisory Committee, Mariel Selbovitz
10.2 Agreement for Member of the Board of Directors, Dr. Roscoe M. Moore Jr.
10.3 Agreement for Member of the Scientific Advisory Committee, Joel L. Zive
10.4 White Coat Strategies LLC Agency Agreement
10.5 Master Agreement for Professional Services
Table of Contents
IMMUNOTECH LABORATORIES, INC. |
|||||
Date: March 15, 2010 | By: | /s/ Ara Ghanime | |||
Ara Ghanime | |||||
President | |||||